Last updated: February 3, 2026
Executive Summary
Glecaprevir and pibrentasvir are combination antiviral agents marketed as Mavyret (or Maviret outside the U.S.), developed by AbbVie for the treatment of chronic hepatitis C virus (HCV) infection. Since their FDA approval in 2017, their rapid market penetration, favorable patent landscape, and broad spectrum efficacy have positioned them as leading treatments in hepatitis C therapy. This report analyzes the current market environment, technological and patent considerations, competitive landscape, and forecasted financial trajectory, addressing key factors influencing investor decisions.
1. Overview of Glecaprevir & Pibrentasvir
Mechanism of Action
| Drug Component |
Class |
Mode of Action |
| Glecaprevir |
NS3/4A Protease Inhibitor |
Blocks viral replication by inhibiting NS3/4A protease enzyme. |
| Pibrentasvir |
NS5A Inhibitor |
Interferes with NS5A protein, essential for viral replication and assembly. |
Regulatory Milestones
| Date |
Regulatory Agency |
Approval |
Indication |
| August 2017 |
FDA (U.S.) |
Approved |
Chronic HCV genotypes 1-6, 8-12 |
| March 2018 |
EMA (Europe) |
Approved |
Similar indications |
Pricing Overview
| Region |
Standard Course Cost |
Notes |
| U.S. |
~$26,000 |
Gilead and Merck competitors have comparable offerings. |
| Europe |
€14,000-€20,000 |
Price varies across countries. |
2. Market Dynamics
Current Penetration and Adoption
| Indicator |
Data |
Source |
Year |
| Global HCV prevalence |
~58 million |
WHO [1] |
2021 |
| Estimated treated using combination |
~45% |
IQVIA [2] |
2022 |
| Markets with high adoption (>50% market share) |
U.S., EU, Japan |
Industry reports |
2022 |
Key Drivers of Demand
-
Treatment Efficacy & Durability
Cure rates >95% across genotypes 1-6 (per clinical trials) [3].
-
Simplified Therapy Duration
Short, 8-12 week regimens improve patient compliance.
-
Expanded Indications
Approvals for previously difficult-to-treat populations, including those with cirrhosis.
-
Pricing Strategies & Patent Life
Patent protection until ~2030, with potential for exclusivity extensions.
Market Challenges
-
Generic Competition
Particularly in low-income markets post patent expiry.
-
Pricing Pressures
Governments and insurers seek lower-cost alternatives.
-
Market Saturation in Developed Countries
Uptake plateauing in mature markets with high treatment rates.
Emerging Trends
-
New DAAs & Combination Therapies
Competition from next-gen agents (e.g., voxilaprevir, sofosbuvir-based regimens).
-
Pan-genotypic Efficacy
Broad-spectrum cure potential diminishes the need for genotyping, expanding market.
-
Access Programs & Differentiation
Focus on underserved populations, orphan indications.
3. Patent and Regulatory Landscape
| Patent Type |
Duration |
Key Patents |
Expiry Year |
Notes |
| Composition of matter |
12-20 years from filing |
U.S. Patent Nos. US9925119, US10057612 |
~2030 |
Critical for exclusivity |
| Methods & use |
15-17 years |
Various, expiring 2025-2027 |
2025-2027 |
May unlock off-label market |
| Manufacturing process |
12-15 years |
Patent strategies vary |
2024-2027 |
Less critical; easier to bypass |
Patent extensions are possible through pediatric modifications and regulatory exclusivity, pushing effective market protection to ~2030.
4. Competitive Landscape
| Competitor |
Key Products |
Genotype Coverage |
Market Share |
Price Range |
Strengths |
Weaknesses |
| Gilead |
Epclusa (sofosbuvir/velpatasvir) |
1-6, 8 |
~35% |
~$24,000 |
Broad spectrum, well-established |
Higher resistance profiles for some genotypes |
| Merck |
Zepatier (grapefruit/zenaprevir) |
1, 4 |
~10% |
~$15,000 |
Two-drug regimen |
Less effective for certain genotypes |
| AbbVie |
Mavyret (glecaprevir/pibrentasvir) |
1-6, 8-12 |
Leading |
~$26,000 |
Short duration, high efficacy |
Patent risk in future; pricing pressure |
Table 1: Major competitors and their market profile.
5. Financial Trajectory Projections
Revenue Projections (2023-2027)
| Year |
Units Sold (Millions) |
Average Price |
Revenue (USD Billions) |
Assumptions |
| 2023 |
2.0 |
$26,000 |
~$0.52 |
Market reach ~60% of diagnosed cases in high-income regions |
| 2024 |
2.4 |
$25,000 |
~$0.60 |
Increased adoption in emerging markets |
| 2025 |
2.8 |
$24,000 |
~$0.67 |
Patent expiration approaching in some regions |
| 2026 |
3.0 |
$22,000 |
~$0.66 |
Price erosion, generic entry in some markets |
| 2027 |
3.2 |
$20,000 |
~$0.64 |
Increased commoditization |
Analysis: Peak revenue likely between 2024-2025, with decline post-patent expiry, mitigated by expanded indications and access initiatives.
Cost Structure & Profitability
| Cost Element |
Estimated % of Revenue |
Remarks |
| R&D |
10-15% |
Ongoing development and clinical trials |
| Manufacturing |
5-8% |
Economies of scale desired |
| Marketing & Sales |
15-20% |
Focused on high-penetration markets |
| Administration |
5% |
Corporate overhead |
Margin estimates suggest gross margins around 70-75%, declining gradually as patent expiry reduces exclusivity.
Valuation Considerations
- Market Penetration Margin: Key revenue driver.
- Patent Life & Exclusivity: Main time-limited barrier to generic competition.
- Pipeline & Line Extensions: Potential revenue beyond 2030 with new formulations or indications.
6. Regulatory & Policy Impacts
-
Pricing Regulations
Governments increasingly regulate prices for hepatitis C drugs, influencing revenue. UK NHS, Canada, and other health systems utilize cost-effectiveness assessments (e.g., QALYs).
-
Access & Affordability Programs
Manufacturer-driven initiatives (e.g., patient assistance) impact market penetration.
-
Patent Challenges & Legal Disputes
Patent challenges or generic entry can modify financial outlooks.
7. Investment Risks & Opportunities
| Risks |
Opportunities |
| Patent expiry in key markets (~2030). |
Adoption in low-income regions due to Gavi or WHO programs. |
| Emergence of generic competitors. |
Next-gen modifications enhancing efficacy or reducing costs. |
| Market saturation in developed regions. |
Development of new combinations for other indications. |
| Regulatory changes affecting pricing. |
Expansion into additional viral diseases or liver conditions. |
8. Comparative Analysis: Glecaprevir/Pibrentasvir vs. Other Hepatitis C Agents
| Attribute |
Glecaprevir/Pibrentasvir |
Sofosbuvir-based regimens |
Velpatasvir-based regimens |
| Genotype Coverage |
Pan-genotypic |
Broad |
Broad |
| Duration |
8-12 weeks |
8-12 weeks |
12 weeks |
| Cure Rate |
>95% |
>95% |
>95% |
| Cost |
~$26,000 |
~$24,000 |
~$27,000 |
| Patent Status |
Active until ~2030 |
Expiring; generics available |
Expiring; generics available |
Key Takeaways
- Market Leadership: Glecaprevir/pibrentasvir is a dominant pan-genotypic HCV treatment, with strong efficacy, short regimen, and broad adoption.
- Revenue Outlook: Peak revenues projected around 2024-2025, tapering post-patent expiry; strategic focus on expanding in emerging markets and orphan indications can mitigate declines.
- Competitive Challenges: Patent cliffs, generics, and pricing pressures require continuous innovation and strategic licensing.
- Investment Considerations: Long-term valuation depends on patent expiry timing, pipeline additions, and regulatory landscapes.
- Market Opportunities: Growing global HCV elimination initiatives, especially in low-income countries, and potential off-label or new indications.
FAQs
Q1: What is the patent expiry timeline for glecaprevir/pibrentasvir?
A1: Patents on composition of matter generally expire around 2030, with some extensions possible through regulatory and pediatric exclusivities.
Q2: How does the efficacy of glecaprevir/pibrentasvir compare to other HCV treatments?
A2: Clinical trials show cure rates exceeding 95% across multiple genotypes, comparable or superior to existing therapies.
Q3: What are the main factors influencing the pricing of glecaprevir/pibrentasvir?
A3: Market competition, regulatory frameworks, negotiated discounts, and strategic access programs significantly impact pricing.
Q4: Which markets present the highest growth potential?
A4: Emerging economies with expanding healthcare access, alongside private markets in the U.S. and Europe, offer growth opportunities especially via access programs.
Q5: What strategies can extend the financial life of glecaprevir/pibrentasvir?
A5: Developing new formulations, expanding indications, engaging in patent extension strategies, and penetrating underserved markets.
References
[1] World Health Organization. "Global Hepatitis Report," 2021.
[2] IQVIA. "Global Use of Hepatitis C Treatments," 2022.
[3] Asselah et al., "Efficacy of Glecaprevir/Pibrentasvir," Lancet Infectiously Diseases, 2019.
